Analysis of cause-specific atherothrombotic cardiovascular disease mortality in Mexico: 2011-2015

Erwin Chiquete1, Jorge Aldrete-Velasco2, Sonia C Juárez-Comboni3

  • 1Instituto Nacional de Ciencias Médicas y de la Nutrición Salvador Zubirán, Mexico.

Insights

Cardiovascular disease (CVD) mortality in Mexico rose from 2011-2015, driven by ischemic heart disease. Men and patients with ischemic heart disease or stroke had shorter survival ages.

Area of Science:

  • Public Health
  • Epidemiology
  • Cardiology

Background:

  • Cardiovascular diseases (CVD) are the leading cause of mortality, disability, and premature death in Mexico.
  • Atherothrombotic CVDs, including ischemic heart disease, heart failure, cerebrovascular disease, and peripheral artery disease, contribute significantly to this burden.

Purpose of the Study:

  • To analyze mortality rates attributed to specific causes of atherothrombotic CVD in Mexico.
  • To examine trends in CVD mortality from 2011 to 2015.

Main Methods:

  • Analysis of 3,105,975 death certificates from January 2011 to December 2015.
  • Utilized the 10th revision of the International Classification of Diseases (ICD) to identify CVD deaths.
  • Conducted regional analyses across Mexican federal states.

Main Results:

  • Examined 594,370 death certificates with CVD as the primary cause.
  • Age-standardized CVD mortality increased from 96.7 to 111.7 per 100,000 people between 2011 and 2015.
  • Ischemic heart disease showed the most significant increase in mortality rates, alongside increases in heart failure, cerebrovascular disease, and peripheral artery disease.
  • Men had a shorter mean age at death (72.04 years) compared to women (77.73 years).
  • Ischemic heart disease and cerebrovascular disease were associated with the shortest survival durations.
  • Mortality increased notably in the older population, with a steep rise in ischemic heart disease deaths over time.

Conclusions:

  • Atherothrombotic CVD mortality in Mexico experienced an increase during the study period, primarily due to ischemic heart disease.
  • Shorter survival ages were observed in men and in individuals affected by ischemic heart disease and stroke.
Abstract

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
308
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
92
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
129